Plain-English translation of NCT05487807 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a simple phone-based program can help people living with HIV quit tobacco use. Researchers are comparing four approaches: basic quit advice alone, advice plus nicotine patches, advice plus text message support, or all three combined. The study will follow participants for 6 months to see which approach works best.
People with HIV who smoke face unique challenges when trying to quit, and there is very little research on what actually works for this group — especially in lower-income countries in Africa. This study aims to find affordable, practical ways to help.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly placed into one of four groups. Some participants receive basic advice to quit, some receive nicotine patches, some receive daily text messages with support and tips, and some receive a combination of patches and text messages. You will visit the clinic at the start and then at 6 months to see how well the treatment worked for you.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Uganda
Zambia
Safety & dosing
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI)
Enrollment target
~800 participants
Started
September 2023
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2023.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.